HaemoCer Instrumentation Advances Plant-sourced Hemostat Applications into Minimally Invasive Surgeries
BAYREUTH, Germany, May 31, 2012 /PRNewswire/ –
BioCer Entwicklungs GmbH (BCE), a German based medical device manufacturer, announces
the CE approval of its advanced HaemoCer(TM) Universal Applicator (UA). HaemoCer(TM) UA is
a delivery configuration for applications of the HaemoCer(TM) Absorbable Polysaccharide
Hemostat (APH) system in minimally invasive surgical procedures.
The HaemoCer(TM) UA system is a unique instrumentation for laparoscopic, ENT, spinal
and other MIS procedures where precise delivery of APH particles to the bleeding site is
mandatory. The delivery instrument is easily attached to the HaemoCer(TM) bellows
dispenser and enables hemostat delivery under direct vision to the wound site for the
control of capillary, venous and arteriolar bleeding. The initial HaemoCer(TM) 5 gram
product range has also expanded to include multiple size configurations meeting the strong
international market demand for HaemoCer(TM) in multidisciplinary procedures.
Dr. Markus Heinlein, Managing Director of BioCer, commented, “The clinical
introduction of HaemoCer(TM) UA offers surgeons a delivery option within the expanding
practice of minimally invasive surgery. Collaborating with leading laparoscopic surgeons
and German engineers, our system has been designed for the controlled release of
hemostatic particles. HaemoCer(TM) UA encompasses 3 unique advances, including a
press-and-release locking system facilitating UA tip placement without uncontrolled
discharge. Secondly the system features a tip design which minimizes tip blockage, both
common difficulties with current particle delivery devices. Finally the new
instrumentation is sold separately and the push-on coupling sheath will accommodate other
devices allowing medical professionals and patients to immediately benefit from this new
instrumentation while converting stocks to HaemoCer(TM).”
BioCer Entwicklungs-GmbH, HaemoCer APH particles are manufactured utilizing a
Polysaccharide Ultra-hydrophilic Resorbable Engineering (PURE) process. HaemoCer(TM)
contains no human or animal components and is developed and manufactured in Germany. For
information, distribution inquiries, and licensing options, please visit
http://www.biocer-gmbh.de or email firstname.lastname@example.org.
Philip MacPherson, email@example.com, +49(0)921-78-77-70-70.
SOURCE BioCer Entwicklungs-GmbH